Alembic Pharmaceuticals gets final approval from USFDA for Clomipramine Hydrochloride Capsules

05 Aug 2021 Evaluate

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Anafranil Capsules, 25 mg, 50 mg, and 75 mg, of SpecGX LLC. Clomipramine Hydrochloride Capsules are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). 

Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg, have an estimated market size of $ 32 million for twelve months ending June 2021. Alembic has a cumulative total of 149 ANDA approvals (131 final approvals and 18 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.


Alembic Pharma Share Price

764.00 -6.85 (-0.89%)
24-Feb-2026 11:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1731.95
Dr. Reddys Lab 1304.55
Cipla 1325.90
Zydus Lifesciences 905.00
Lupin 2245.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×